Cyclin With Growth Factors
MHP's Cyclin With Growth Factors is a vitamin and mineral combination supplement, earning an N+ Score of 78 and a B- grade, placing it in the 'good' tier. This product features a concise total of 4 ingredients, demonstrating 100% label transparency. Key ingredients like Vitamin B6 at 10.5mg, Magnesium at 450mg, and Zinc at 30mg are all present at clinically studied doses, which research suggests may support various physiological functions. The formula's strength lies in its adequately dosed core vitamins and minerals. This supplement may be suitable for individuals seeking to support general vitamin and mineral intake with specific, well-dosed components.
About This Product
Cyclin With Growth Factors by MHP is a vitamins & minerals supplement containing 4 active ingredients. It has earned an N+ Score of 78/100 (Grade B-).
This product features a fully transparent label with individual ingredient amounts disclosed, and key ingredients are present at clinically effective doses based on peer-reviewed research.
Notable clinical-dose ingredients include Vitamin B6, Magnesium, Zinc.
N+ Score Breakdown
Are key ingredients present at clinically effective doses based on research?
Does the product include all expected ingredients for its supplement category?
Are individual ingredient amounts clearly disclosed without proprietary blends?
Does the formula include a breadth of beneficial compounds from multiple pathways?
Strengths
- +Key ingredients at clinically effective doses
- +Fully transparent label with individual ingredient amounts disclosed
- +3 ingredient(s) at clinical dose levels
Weaknesses
- −No major weaknesses identified
Ingredient Analysis (4 ingredients)
| Ingredient | Amount | Dose Adequacy |
|---|---|---|
| Vitamin B6 | 10.500 mg | Optimal |
| Magnesium | 450.000 mg | High |
| Zinc | 30.000 mg | Optimal |
| Full Phase Muscle Precursor Cell Growth Factors | 1135.500 mg | N/A |
Clinical ranges based on NIH ODS Fact Sheets and peer-reviewed research. Status indicates whether the amount meets evidence-based thresholds.